Philippe Labrune

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11807086/publications.pdf

Version: 2024-02-01

55 papers	3,690 citations	172457 29 h-index	155660 55 g-index
56 all docs	56 docs citations	56 times ranked	3335 citing authors

#	Article	IF	Citations
1	Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy. Human Molecular Genetics, 2022, 31, 914-928.	2.9	4
2	Disease burden and management of <scp>Criglerâ€Najjar</scp> syndrome: Report of a world registry. Liver International, 2022, 42, 1593-1604.	3.9	8
3	The Glycogen Storage Diseases and Related Disorders. , 2022, , 179-200.		2
4	Puberty and fertility in classic galactosemia. Endocrine Connections, 2021, 10, 240-247.	1.9	6
5	Narrative review of glycogen storage disorder type <scp>III</scp> with a focus on neuromuscular, cardiac and therapeutic aspects. Journal of Inherited Metabolic Disease, 2021, 44, 521-533.	3.6	9
6	Papillary renal cell carcinoma in two young adults with glycogen storage disease type Ia. JIMD Reports, 2020, 52, 17-22.	1.5	2
7	Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. Molecular Genetics and Metabolism Reports, 2020, 23, 100581.	1.1	12
8	Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. Acta Neuropathologica Communications, 2019, 7, 167.	5.2	17
9	Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Criglerâ€“Najjar Syndrome. Human Gene Therapy, 2019, 30, 1297-1305.	2.7	39
10	Wholeâ€Body Muscle Magnetic Resonance Imaging in Glycogenâ€Storage Disease Type III. Muscle and Nerve, 2019, 60, 72-79.	2.2	6
11	Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	1.3	290
12	Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa. Molecular Genetics and Metabolism, 2017, 122, 108-116.	1.1	11
13	International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and followâ€up. Journal of Inherited Metabolic Disease, 2017, 40, 171-176.	3.6	132
14	Clinical heterogeneity and phenotype/genotype findings in 5 families with GYG1 deficiency. Neurology: Genetics, 2017, 3, e208.	1.9	12
15	Fertility in adult women with classic galactosemia and primary ovarian insufficiency. Fertility and Sterility, 2017, 108, 168-174.	1.0	42
16	Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. Journal of Inherited Metabolic Disease, 2016, 39, 697-704.	3.6	110
17	Progressive development of renal cysts in glycogen storage disease type I. Human Molecular Genetics, 2016, 25, 3784-3797.	2.9	20
18	Cross-sectional retrospective study of muscle function in patients with glycogen storage disease type III. Neuromuscular Disorders, 2016, 26, 584-592.	0.6	13

#	Article	IF	Citations
19	Peripheral neuropathy in glycogen storage disease type III: Fact or myth?. Muscle and Nerve, 2016, 53, 310-312.	2.2	7
20	No Perinatal HIV-1 Transmission From Women With Effective Antiretroviral Therapy Starting Before Conception. Clinical Infectious Diseases, 2015, 61, civ578.	5.8	180
21	Correction of Hyperbilirubinemia in Gunn Rats by Surgical Delivery of Low Doses of Helper-Dependent Adenoviral Vectors. Human Gene Therapy Methods, 2014, 25, 181-186.	2.1	13
22	Exercise intolerance in Glycogen Storage Disease Type III: Weakness or energy deficiency?. Molecular Genetics and Metabolism, 2013, 109, 14-20.	1.1	38
23	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. Journal of Hepatology, 2013, 58, 350-357.	3.7	146
24	Is Intrapartum Intravenous Zidovudine for Prevention of Mother-to-Child HIV-1 Transmission Still Useful in the Combination Antiretroviral Therapy Era?. Clinical Infectious Diseases, 2013, 57, 903-914.	5.8	113
25	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. Journal of Hepatology, 2012, 56, 184-191.	3.7	354
26	Glucose-6-phosphatase deficiency. Orphanet Journal of Rare Diseases, 2011, 6, 27.	2.7	192
27	Perioperative Management of Hemostasis for Surgery of Benign Hepatic Adenomas in Patients with Glycogen Storage Disease Type Ia. JIMD Reports, 2011, 1, 97-106.	1.5	8
28	Successful Plasmapheresis for Acute and Severe Unconjugated Hyperbilirubinemia in a Child with Crigler Najjar Type I Syndrome. JIMD Reports, 2011, 2, 33-36.	1.5	9
29	Successful Treatment of Severe Cardiomyopathy in Glycogen Storage Disease Type III With D,L-3-Hydroxybutyrate, Ketogenic and High-Protein Diet. Pediatric Research, 2011, 70, 638-641.	2.3	96
30	Lentiviral Vectors That Express UGT1A1 in Liver and Contain miR-142 Target Sequences Normalize Hyperbilirubinemia in Gunn Rats. Gastroenterology, 2010, 139, 999-1007.e2.	1.3	32
31	Investigating glycogenosis type III patients with multi-parametric functional NMR imaging and spectroscopy. Neuromuscular Disorders, 2010, 20, 548-558.	0.6	34
32	KlÃ¼ver Bucy syndrome following hypoglycaemic coma in a patient with glycogen storage disease type Ib. Journal of Inherited Metabolic Disease, 2010, 33, 477-480.	3.6	1
33	The Tunisian population history through the Criglerâ€“Najjar type I syndrome. European Journal of Human Genetics, 2008, 16, 848-853.	2.8	13
34	Successful Pregnancy in a Criglerâ€“Najjar Type I Patient Treated by Phototherapy and Semimonthly Albumin Infusions. Gastroenterology, 2006, 131, 921-924.	1.3	16
35	Further Evidence That the UGT1A1*28 Allele Is Not Associated with Coronary Heart Disease: The ECTIM Study. Clinical Chemistry, 2006, 52, 2313-2314.	3.2	35
36	Paternal isodisomy for chromosome 2 as the cause of Criglerâ€“Najjar type I syndrome. European Journal of Human Genetics, 2005, 13, 278-282.	2.8	35

#	Article	IF	Citations
37	Increased Levels of Hemostatic Proteins are Independent of Inflammation in Glycogen Storage Disease Type Ia. Journal of Pediatric Gastroenterology and Nutrition, 2003, 37, 566-570.	1.8	7
38	Crigler-Najjar syndrome type I in Tunisia may be associated with a founder effect related to the Q357R mutation within theUGT1 gene. Human Mutation, 2002, 19, 570-571.	2.5	11
39	Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). European Journal of Pediatrics, 2002, 161, S20-S34.	2.7	205
40	Glycogen storage disease type I: indications for liver and/or kidney transplantation. European Journal of Pediatrics, 2002, 161, S53-S55.	2.7	39
41	Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1. European Journal of Pediatrics, 2002, 161, S83-S87.	2.7	68
42	Contraception and pregnancy in women affected by glycogen storage diseases. European Journal of Pediatrics, 2002, 161, S97-S101.	2.7	15
43	Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). European Journal of Pediatrics, 2002, 161, S112-S119.	2.7	89
44	Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1. European Journal of Pediatrics, 2002, 161, S120-S123.	2.7	55
45	Prenatal diagnosis of Crigler-Najjar syndrome type I by single-strand conformation polymorphism (SSCP). Prenatal Diagnosis, 2002, 22, 914-916.	2.3	13
46	Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European study on glycogen storage disease type I (ESGSD I). European Journal of Pediatrics, 2002, 161, S20-S34.	2.7	233
47	Glycogen storage disease type I: indications for liver and/or kidney transplantation. European Journal of Pediatrics, 2002, 161, S53-S55.	2.7	39
48	Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European study on glycogen storage disease type 1. European Journal of Pediatrics, 2002, 161, S83-S87.	2.7	55
49	Severe pulmonary arterial hypertension in type 1 glycogen storage disease. European Journal of Pediatrics, 2002, 161, S93-S96.	2.7	30
50	Contraception and pregnancy in women affected by glycogen storage diseases. European Journal of Pediatrics, 2002, 161, S97-S101.	2.7	13
51	Guidelines for management of glycogen storage disease type Iâ€"European study on glycogen storage disease type I (ESGSD I). European Journal of Pediatrics, 2002, 161, S112-S119.	2.7	154
52	Consensus guidelines for management of glycogen storage disease type 1bâ€"European study on glycogen storage disease type 1. European Journal of Pediatrics, 2002, 161, S120-S123.	2.7	44
53	Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: Results of the European Study on Glycogen Storage Disease Type I. Journal of Pediatrics, 2000, 137, 187-191.	1.8	222
54	Hepatocellular Adenomas in Glycogen Storage Disease Type I and III: A Series of 43 Patients and Review of the Literature. Journal of Pediatric Gastroenterology and Nutrition, 1997, 24, 276-279.	1.8	272

#	Article	IF	Citations
55	Genetic heterogeneitiy of Crigler-Najjar syndrome type I: A study of 14 cases. Human Genetics, 1994, 94, 693-7.	3.8	62